

### **Prior Authorization Review Panel**

### **CHC-MCO Policy Submission**

A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: 11/2021	
Policy Number: PHW.PDL.010	Effective Date: 01/01/2020 Revision Date: 10/2021	
Policy Name: Ulcerative Colitis Agents		
Type of Submission – <u>Check all that apply</u> :		
<ul><li>□ New Policy</li><li>✓ Revised Policy*</li></ul>		
☐ Annual Review - No Revisions ✓ Statewide PDL - Select this box when submitting policies for drug classes included on the Statewide PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitting policies for drug classes included on the State PDL - Select this box when submitted in the State PDL - Select this box when submitted in the State PDL - Select this box when submitted in the State PDL - Select this box when submitted in the State PDL - Select this box when submitted in the State PDL - Select this box when submitted in the State PDL - Select this box when submitted in the State PDL - Select this box when submitted in the State PDL - Select this box when submitted in the State PDL - Select this box when submitted in the State PDL - Select this box when submitted in the State PDL - Select this box when submitted in the State PDL - Select this box		
*All revisions to the policy <u>must</u> be highlighted using track chan	nges throughout the document.	
Please provide any changes or clarifying information for the pol	licy below:	
Q1 2022: revised according to DHS revisions effective 01/03/2022		
Name of Authorized Individual (Please type or print):	Signature of Authorized Individual:	
Venkateswara R. Davuluri, MD	C Raulun	

# CLINICAL POLICY Ulcerative Colitis Agents



## **Clinical Policy: Ulcerative Colitis Agents**

Reference Number: PHW.PDL.010

Effective Date: 01/01/2020 Last Review Date: 10/2021

**Revision Log** 

#### Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with PA Health and Wellness® that Ulcerative Colitis Agents are **medically necessary** when the following criteria are met:

#### I. Requirements for Prior Authorization of Ulcerative Colitis Agents

#### A. <u>Prescriptions That Require Prior Authorization</u>

Prescriptions for Ulcerative Colitis Agents that meet any of the following conditions must be prior authorized:

- 1. A non-preferred Ulcerative Colitis Agent. See the Preferred Drug List (PDL) for the list of preferred Ulcerative Colitis Agents at: <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a>.
- 2. A prescription for Zeposia (ozanimod).
- 3. An Ulcerative Colitis Agent with a prescribed quantity that exceeds the quantity limit.

#### B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for an Ulcerative Colitis Agent, the determination of whether the requested prescription is medically necessary will take into account whether the member:

- 1. For Zeposia (ozanimod), see PHW.PDL.043.02 Ozanimod (Zeposia); OR
- 2. For a non-preferred Ulcerative Colitis Agent, **one** of the following:
  - a. Has a history of therapeutic failure, contraindication, or intolerance of the preferred Ulcerative Colitis Agents
  - b. Has a current history (within the past 90 days) of being prescribed the same non-preferred Ulcerative Colitis Agent (does not apply to non-preferred brands when the therapeutically equivalent generic is preferred or to non-preferred generics when the therapeutically equivalent brand is preferred);

**AND** 

# CLINICAL POLICY Ulcerative Colitis Agents



3. If a prescription for an Ulcerative Colitis Agent is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in PA.CP.PMN.59 Quantity Limit Override.

NOTE: If the member does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the member, the request for prior authorization will be approved.

#### C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for an Ulcerative Colitis Agent. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the member.

#### D. Approval Duration: 12 months

Reviews, Revisions, and Approvals	Date
Policy created	01/01/2020
Q3 2020 annual review: no changes.	07/2020
Q1 2021 annual review: no changes.	01/2021
Q1 2022: revised according to DHS revisions effective 01/03/2022	10/2021